Some serum proteins, such as the prostate specific antigen (PSA) in prostate cancer (PCa) and carcinoembryonic antigen (CEA) in colorectal cancer, are well established biomarkers and clinically widely used, although their correlation with other disease progression parameters is not always ideal [2,3]. The gene discussed is CEACAM5; the disease is prostate carcinoma.